Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Active not recruiting 4Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Mantle-Cell 21Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 5Waldenstrom Macroglobulinemia 4Lymphoma, Follicular 4Leukemia, B-Cell 4Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Recurrence 1Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1Chromosome 17 deletion 1Cardiovascular Diseases 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 49Rituximab 32fludarabine 30Doxorubicin 14Specimen Handling 13Magnetic Resonance Spectroscopy 13Vincristine 12Prednisone 12fludarabine phosphate 11pirtobrutinib 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Immunotherapy, Adoptive 8Biopsy 8venetoclax 7polatuzumab vedotin 7pembrolizumab 7glofitamab 7zanubrutinib 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × acalabrutinib × 1 year × Clear all
NCT04662255 2026-05-15

BRUIN-MCL-321

Eli Lilly and Company

Phase 3 Active not recruiting
500 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04529772 2026-03-31

ESCALADE

Acerta Pharma BV

Phase 3 Active not recruiting
611 enrolled
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Massachusetts General Hospital

Phase 2 Active not recruiting
28 enrolled 6 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT04257578 2025-10-08

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

University of Washington

Phase 1/2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡